Remineralization Efficacy of Moringa Oleifera Varnish Vs MI Varnish in Initial Carious Lesions Over 6 Months Follow Up: a Randomized Controlled Clinical Trial
Launched by CAIRO UNIVERSITY · Mar 25, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a special varnish made from Moringa Oleifera in helping to repair early tooth decay, specifically targeting white spot lesions (WSLs) on smooth surfaces of teeth. Researchers want to see if this Moringa varnish works as well as an established treatment known as MI varnish, which has been shown to help in reversing early cavities. The trial will include adults aged 25 to 35 who have at least one active white spot lesion, maintain good oral hygiene, and are willing to participate in the study.
If you qualify for this trial, you can expect to receive either the Moringa Oleifera varnish or the MI varnish treatment. The study will follow participants for six months to see how well each treatment helps in remineralizing the teeth. It's important to note that participants should not have certain conditions, like severe gum disease or cognitive impairments, which could affect their ability to take part in the trial. Overall, this research aims to find effective ways to treat early tooth decay and improve dental health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria of participants:
- • Presentation with at least one active WSLs on the study teeth at the start of the study.
- • Good oral hygiene.
- • Co-operative patients approving to participate in the trial.
- • Have sufficient cognitive ability to understand consent procedures Inclusion criteria of teeth.
- • Active non-cavitated initial carious lesions (ICDAS 1\&2)
- • DIAGNOdent score between (8-15)
- • Vital teeth with no signs or symptoms of irreversible pulpitis.
- • No signs of clinical mobility.
- • Teeth with healthy periodontium.
- Exclusion Criteria of participants:
- • Participants with parafunctional habits or bruxism.
- • Participants with dry mouth.
- • Participants with systemic diseases or disabilities that may affect participation.
- • Heavy smoking.
- • Pregnancy.
- • Lack of compliance.
- • Severe or active periodontal disease.
- • Cognitive impairment
- Exclusion criteria of teeth:
- • DIAGNOdent score less than 8 and more than 15
- • Untreated cavitated lesions or extensive restorations on the facial surfaces of the study teeth
- • Intrinsic or extremely heavy extrinsic staining
- • Periapical pathosis or signs of pulpal pathology.
- • Non-vital tooth.
- • Signs of pathological wear.
- • Endodontically treated tooth.
- • Severe periodontal affection or tooth indicated for extraction.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Ahmed Zohair El-Hoshy, professor at Cairo University
Principal Investigator
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported